688180.SS
Shanghai Junshi Biosciences Co., Ltd.
688180.SS
(0.5)31,34 CNY
-17.76% ROA
-27.05% ROE
-18.91x PER
28.440.881.340,00 CNY
39.55% DER
0% Yield
-311.46% NPM
Shanghai Junshi Biosciences Co., Ltd. Stock Analysis
Shanghai Junshi Biosciences Co., Ltd. Fundamental Analysis
Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.
| # | Analysis | Rating |
|---|---|---|
| 1 |
DER
The stock has a minimal amount of debt (14%) relative to its ownership, showcasing a strong financial position and lower risk for investors. |
|
| 2 |
ROE
Negative ROE (-29.57%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity. |
|
| 3 |
ROA
The stock's ROA (-20.71%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment. |
|
| 4 |
PBV
The stock's elevated P/BV ratio (4.09x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value. |
|
| 5 |
Revenue Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 6 |
Net Profit Growth
Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect. |
|
| 7 |
Assets Growth
Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity. |
|
| 8 |
Graham Number
The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity. |
|
| 9 |
Dividend Growth
The company's dividend growth has remained flat for the past three years, offering no indication of improved returns and making it a less advantageous investment opportunity. |
|
| 10 |
Dividend
Investors should be cautious as the company hasn't distributed dividends in the last three years, possibly indicating financial challenges. |
|
| 11 |
Buffet Intrinsic Value
The company's stock shows signs of being overvalued (-40) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value. |
Shanghai Junshi Biosciences Co., Ltd. Technical Analysis
Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.
| # | Analysis | Recommendation |
|---|---|---|
| 1 | Awesome Oscillator | Hold |
| 2 | MACD | Sell |
| 3 | RSI | Hold |
| 4 | Stoch RSI | Hold |
Shanghai Junshi Biosciences Co., Ltd. Price Chart
Financial Statements
Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.
Income Statements
An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.
Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.
| Year | Revenue | Growth |
|---|---|---|
| 2014 | 5.801.886 | |
| 2015 | 2.886.792 | -100.98% |
| 2016 | 3.757.000 | 23.16% |
| 2017 | 1.148.000 | -227.26% |
| 2018 | 934.000 | -22.91% |
| 2019 | 775.089.000 | 99.88% |
| 2020 | 1.594.897.000 | 51.4% |
| 2021 | 4.024.841.000 | 60.37% |
| 2022 | 1.453.493.000 | -176.91% |
| 2023 | -2.678.812.000 | 154.26% |
| 2023 | 1.482.845.594 | 280.65% |
| 2024 | 1.621.006.912 | 8.52% |
Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.
| Year | Research and Development Expenses | Growth |
|---|---|---|
| 2014 | 29.687.713 | |
| 2015 | 0 | 0% |
| 2016 | 122.001.000 | 100% |
| 2017 | 275.303.000 | 55.68% |
| 2018 | 538.183.000 | 48.85% |
| 2019 | 946.100.000 | 43.12% |
| 2020 | 1.778.023.000 | 46.79% |
| 2021 | 2.068.739.000 | 14.05% |
| 2022 | 2.384.373.000 | 13.24% |
| 2023 | 1.288.110.596 | -85.11% |
| 2023 | 1.813.224.562 | 28.96% |
| 2024 | 1.080.335.500 | -67.84% |
General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.
| Year | General and Administrative Expenses | Growth |
|---|---|---|
| 2014 | 42.834.011 | |
| 2015 | 83.846.043 | 48.91% |
| 2016 | 42.760.000 | -96.09% |
| 2017 | 73.752.000 | 42.02% |
| 2018 | 124.837.000 | 40.92% |
| 2019 | 244.229.000 | 48.89% |
| 2020 | 443.346.000 | 44.91% |
| 2021 | 647.950.000 | 31.58% |
| 2022 | 578.269.000 | -12.05% |
| 2023 | 469.712.749 | -23.11% |
| 2023 | 556.808.000 | 15.64% |
| 2024 | 1.010.396.000 | 44.89% |
EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.
| Year | EBITDA | Growth |
|---|---|---|
| 2014 | -39.331.759 | |
| 2015 | -73.974.085 | 46.83% |
| 2016 | -136.584.000 | 45.84% |
| 2017 | -277.320.000 | 50.75% |
| 2018 | -649.280.000 | 57.29% |
| 2019 | -704.853.000 | 7.88% |
| 2020 | -1.527.716.000 | 53.86% |
| 2021 | -422.772.000 | -261.36% |
| 2022 | -2.377.972.000 | 82.22% |
| 2023 | -1.165.274.092 | -104.07% |
| 2023 | -2.181.511.830 | 46.58% |
| 2024 | -1.289.542.931 | -69.17% |
Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.
| Year | Gross Profit | Growth |
|---|---|---|
| 2014 | 2.113.407 | |
| 2015 | 2.754.098 | 23.26% |
| 2016 | 2.771.000 | 0.61% |
| 2017 | 702.000 | -294.73% |
| 2018 | 667.000 | -5.25% |
| 2019 | 684.405.000 | 99.9% |
| 2020 | 1.222.366.000 | 44.01% |
| 2021 | 2.766.654.000 | 55.82% |
| 2022 | 927.211.000 | -198.38% |
| 2023 | -2.678.812.000 | 134.61% |
| 2023 | 698.621.470 | 483.44% |
| 2024 | 1.210.179.728 | 42.27% |
Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.
| Year | Net Profit | Growth |
|---|---|---|
| 2014 | -25.253.952 | |
| 2015 | -57.970.317 | 56.44% |
| 2016 | -131.967.000 | 56.07% |
| 2017 | -321.071.000 | 58.9% |
| 2018 | -716.414.000 | 55.18% |
| 2019 | -744.233.000 | 3.74% |
| 2020 | -1.665.639.000 | 55.32% |
| 2021 | -728.181.000 | -128.74% |
| 2022 | -2.582.095.000 | 71.8% |
| 2023 | -1.641.589.611 | -57.29% |
| 2023 | -2.283.431.860 | 28.11% |
| 2024 | -1.450.647.669 | -57.41% |
EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.
| Year | Earning per Share (EPS) | Growth |
|---|---|---|
| 2014 | 0 | |
| 2015 | 0 | 0% |
| 2016 | 0 | 0% |
| 2017 | 0 | 0% |
| 2018 | -1 | 100% |
| 2019 | -1 | 0% |
| 2020 | -2 | 100% |
| 2021 | -1 | 0% |
| 2022 | -3 | 100% |
| 2023 | 0 | 0% |
| 2023 | -2 | 100% |
| 2024 | -1 | -100% |
Cashflow Statements
Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.
Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.
| Year | Free Cashflow | Growth |
|---|---|---|
| 2014 | -82.093.830 | |
| 2015 | -155.030.112 | 47.05% |
| 2016 | -384.996.000 | 59.73% |
| 2017 | -681.002.000 | 43.47% |
| 2018 | -1.068.129.000 | 36.24% |
| 2019 | -2.050.183.000 | 47.9% |
| 2020 | -2.091.488.000 | 1.97% |
| 2021 | -1.528.129.000 | -36.87% |
| 2022 | -2.169.277.000 | 29.56% |
| 2023 | -839.170.675 | -158.5% |
| 2023 | -2.731.706.549 | 69.28% |
| 2024 | -183.422.098 | -1389.3% |
Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.
| Year | Operating Cashflow | Growth |
|---|---|---|
| 2014 | -39.189.540 | |
| 2015 | -82.027.829 | 52.22% |
| 2016 | -185.207.000 | 55.71% |
| 2017 | -347.076.000 | 46.64% |
| 2018 | -510.758.000 | 32.05% |
| 2019 | -1.187.034.000 | 56.97% |
| 2020 | -1.498.806.000 | 20.8% |
| 2021 | -641.901.000 | -133.49% |
| 2022 | -1.775.325.000 | 63.84% |
| 2023 | -435.939.195 | -307.24% |
| 2023 | -1.899.132.021 | 77.05% |
| 2024 | 0 | 0% |
Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.
| Year | Capital Expenditure | Growth |
|---|---|---|
| 2014 | 42.904.290 | |
| 2015 | 73.002.283 | 41.23% |
| 2016 | 199.789.000 | 63.46% |
| 2017 | 333.926.000 | 40.17% |
| 2018 | 557.371.000 | 40.09% |
| 2019 | 863.149.000 | 35.43% |
| 2020 | 592.682.000 | -45.63% |
| 2021 | 886.228.000 | 33.12% |
| 2022 | 393.952.000 | -124.96% |
| 2023 | 403.231.480 | 2.3% |
| 2023 | 832.574.528 | 51.57% |
| 2024 | 183.422.098 | -353.91% |
Balance Sheet
Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.
Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.
| Year | Equity | Growth |
|---|---|---|
| 2014 | 315.233.454 | |
| 2015 | 607.287.806 | 48.09% |
| 2016 | 1.126.615.000 | 46.1% |
| 2017 | 1.119.334.000 | -0.65% |
| 2018 | 3.321.133.000 | 66.3% |
| 2019 | 2.988.516.000 | -11.13% |
| 2020 | 5.841.260.000 | 48.84% |
| 2021 | 8.332.182.000 | 29.9% |
| 2022 | 9.794.250.000 | 14.93% |
| 2023 | 8.804.291.000 | -11.24% |
| 2023 | 7.320.610.471 | -20.27% |
| 2024 | 6.623.420.000 | -10.53% |
Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.
| Year | Assets | Growth |
|---|---|---|
| 2014 | 332.939.600 | |
| 2015 | 628.380.383 | 47.02% |
| 2016 | 1.149.030.000 | 45.31% |
| 2017 | 1.219.709.000 | 5.79% |
| 2018 | 4.257.310.000 | 71.35% |
| 2019 | 4.422.440.000 | 3.73% |
| 2020 | 8.010.864.000 | 44.79% |
| 2021 | 11.050.720.000 | 27.51% |
| 2022 | 12.576.286.000 | 12.13% |
| 2023 | 11.798.257.000 | -6.59% |
| 2023 | 11.342.866.871 | -4.01% |
| 2024 | 11.007.876.000 | -3.04% |
Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.
| Year | Liabilities | Growth |
|---|---|---|
| 2014 | 13.072.218 | |
| 2015 | 14.162.581 | 7.7% |
| 2016 | 22.415.000 | 36.82% |
| 2017 | 100.375.000 | 77.67% |
| 2018 | 936.177.000 | 89.28% |
| 2019 | 1.433.924.000 | 34.71% |
| 2020 | 2.169.604.000 | 33.91% |
| 2021 | 2.718.538.000 | 20.19% |
| 2022 | 2.782.036.000 | 2.28% |
| 2023 | 2.993.966.000 | 7.08% |
| 2023 | 3.838.792.830 | 22.01% |
| 2024 | 4.384.456.000 | 12.45% |
Shanghai Junshi Biosciences Co., Ltd. Financial Ratio (TTM)
Valuation Metrics
- Revenue per Share
- 0.63
- Net Income per Share
- -1.96
- Price to Earning Ratio
- -18.91x
- Price To Sales Ratio
- 45.83x
- POCF Ratio
- -34.75
- PFCF Ratio
- -13.68
- Price to Book Ratio
- 5.63
- EV to Sales
- 45.6
- EV Over EBITDA
- -15.86
- EV to Operating CashFlow
- -26.91
- EV to FreeCashFlow
- -13.61
- Earnings Yield
- -0.05
- FreeCashFlow Yield
- -0.07
- Market Cap
- 28,44 Bil.
- Enterprise Value
- 28,30 Bil.
- Graham Number
- 17.06
- Graham NetNet
- -0.81
Income Statement Metrics
- Net Income per Share
- -1.96
- Income Quality
- 0.67
- ROE
- -0.27
- Return On Assets
- -0.18
- Return On Capital Employed
- -0.22
- Net Income per EBT
- 0.98
- EBT Per Ebit
- 1.06
- Ebit per Revenue
- -3.01
- Effective Tax Rate
- -0.05
Margins
- Sales, General, & Administrative to Revenue
- 1.08
- Research & Developement to Revenue
- 2.43
- Stock Based Compensation to Revenue
- 0.01
- Gross Profit Margin
- 0.1
- Operating Profit Margin
- -3.01
- Pretax Profit Margin
- -3.19
- Net Profit Margin
- -3.11
Dividends
- Dividend Yield
- 0
- Dividend Yield %
- 0
- Payout Ratio
- -0.02
- Dividend Per Share
- 0
Operating Metrics
- Operating Cashflow per Share
- -1.07
- Free CashFlow per Share
- -2.11
- Capex to Operating CashFlow
- -0.98
- Capex to Revenue
- 1.65
- Capex to Depreciation
- 3.99
- Return on Invested Capital
- -0.22
- Return on Tangible Assets
- -0.18
- Days Sales Outstanding
- 0
- Days Payables Outstanding
- 160.46
- Days of Inventory on Hand
- 360.65
- Receivables Turnover
- 0
- Payables Turnover
- 2.27
- Inventory Turnover
- 1.01
- Capex per Share
- 1.04
Balance Sheet
- Cash per Share
- 3,36
- Book Value per Share
- 6,72
- Tangible Book Value per Share
- 6.6
- Shareholders Equity per Share
- 6.6
- Interest Debt per Share
- 2.64
- Debt to Equity
- 0.4
- Debt to Assets
- 0.23
- Net Debt to EBITDA
- 0.08
- Current Ratio
- 2.07
- Tangible Asset Value
- 6,50 Bil.
- Net Current Asset Value
- 0,44 Bil.
- Invested Capital
- 7174625000
- Working Capital
- 2,49 Bil.
- Intangibles to Total Assets
- 0.01
- Average Receivables
- 0,36 Bil.
- Average Payables
- 0,68 Bil.
- Average Inventory
- 544827630.5
- Debt to Market Cap
- 0.09
Dividends
Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.
| Year | Dividends | Growth |
|---|
Shanghai Junshi Biosciences Co., Ltd. Profile
About Shanghai Junshi Biosciences Co., Ltd.
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
- CEO
- Mr. Cong Li
- Employee
- 2.532
- Address
-
Building 7
Shanghai, 200126
Shanghai Junshi Biosciences Co., Ltd. Executives & BODs
| # | Name | Age |
|---|---|---|
| 1 |
Ms. Lu Yuan Assistant to GM & Chief of Internal Audit Department |
70 |
| 2 |
Dr. Jianjun Zou M.D., Ph.D. GM, Chief Executive Officer & Executive Director |
70 |
| 3 |
Dr. Ning Li Executive Vice-Chairman of the Board |
70 |
| 4 |
Dr. Sheng Yao Ph.D. Senior Vice President & Executive Director |
70 |
| 5 |
Dr. Gang Wang Deputy GM, Chief Quality Officer, Senior Vice President of Industry Affairs & Executive Director |
70 |
| 6 |
Dr. Xin Li Executive Director |
70 |
| 7 |
Mr. Jun Xiong Executive Chairman |
70 |
| 8 |
Mr. Cong Li Co-Chief Executive Officer & Executive Director |
70 |
| 9 |
Mr. Baohong Xu Financial Director |
70 |
| 10 |
Mr. Zhuobing Zhang Deputy GM & Executive Director |
70 |
Shanghai Junshi Biosciences Co., Ltd. Competitors
